

DAFTAR PUSTAKA

- Ambasudhan, R., Talantova, M., Coleman, R., Yuan, X., Zhu, S., Lipton, S. A., & Ding, S. (2011). Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. *Cell stem cell*, 9(2), 113–118.
- Astuti, I., & Ysrafil. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and pejamu response. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 14(4), 407–412.
- Atluri, S., Manchikanti, L., & Hirsch, J. A. (2020). Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ILL COVID-19 patients: The case for compassionate use. *Pain Physician*, 23(2), E71–E84.
- Caplan A. I. (2017). Mesenchymal Stem Cells: Time to Change the Name!. *Stem cells translational medicine*, 6(6), 1445–1451.
- Channappanavar, R., & Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Seminars in Immunopathology*, 39(5), 529–539.
- Culp, W. C. (2020). Coronavirus Disease 2019. *A & A Practice*, 14(6), e01218.
- Deng, Y., Zhang, Y., Ye, L., Zhang, T., Cheng, J., Chen, G., Zhang, Q., & Yang, Y. (2016). Umbilical Cord-derived Mesenchymal Stem Cells Instruct Monocytes Towards an IL10-producing Phenotype by Secreting IL6 and HGF. *Scientific Reports*, 6(1), 37566.
- Dolhnikoff, M., Duarte-Neto, A. N., de Almeida Monteiro, R. A., da Silva, L. F. F., de Oliveira, E. P., Saldiva, P. H. N., Mauad, T., & Negri, E. M. (2020). Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. *Journal of Thrombosis and Haemostasis*, 18(6), 1517–1519.
- Echaide, M., Autilio, C., Arroyo, R., & Perez-gil, J. (2017). AC NU SC. BBA - Biomembranes.
- Fields, B. N., Knipe, D. M., Howley, P. M., & Griffin, D. E. (2001). *Fields virology*. Philadelphia: Lippincott Williams & Wilkins.

- Fischer, U. M., Harting, M. T., Jimenez, F., Monzon-Posadas, W. O., Xue, H., Savitz, S. I., Laine, G. A., & Cox, C. S., Jr (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem cells and development*, 18(5), 683–692.
- Gebler, A., Zabel, O., & Seliger, B. (2012). The immunomodulatory capacity of mesenchymal stem cells. *Trends in Molecular Medicine*, 18(2)
- George, M. J., Prabhakara, K., Toledano-Furman, N. E., Gill, B. S., Wade, C. E., Cotton, B. A., Cap, A. P., Olson, S. D., & Cox Jr, C. S. (2020). Procoagulant in vitro effects of clinical cellular therapeutics in a severely injured trauma population. *Stem Cells Translational Medicine*, 9(4), 491–498.
- Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D., Siano, M., Oreni, L., Rusconi, S., Gervasoni, C., Ridolfo, A. L., Rizzardini, G., Antinori, S., & Galli, M. (2020). Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, ciaa330. Advance online publication.
- Golchin, A. (2020). Mesenchymal Stem Cell Therapy for COVID-19 : Present or Future.
- Golchin, A., Farahany, T. Z., Khojasteh, A., Soleimanifar, F., & Ardeshiryajimi, A. (2019). The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review. *Current Stem Cell Research & Therapy*, 14(1), 22–33.
- Hare, J. M., Fishman, J. E., Gerstenblith, G., DiFede Velazquez, D. L., Zambrano, J. P., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V, Brinker, J. A., Breton, E., Davis-Sproul, J., Schulman, I. H., Byrnes, J., Mendizabal, A. M., Lowery, M. H., Rouy, D., Altman, P., Wong Po Foo, C., ... Lardo, A. (2012). Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA*, 308(22), 2369–2379.

- Hosseini, S., Taghiyar, L., Safari, F., & Baghaban Eslaminejad, M. (2018). Regenerative Medicine Applications of Mesenchymal Stem Cells. *Advances in Experimental Medicine and Biology*, 1089, 115–141.
- Hu, R., Han, C., Pei, S., Yin, M., & Chen, X. (2020). Procalcitonin levels in COVID-19 patients. *International Journal of Antimicrobial Agents*, 56(2), 106051.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., & Gu, X. (2020). Articles Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. *6736(20)*, 1–10.
- Irmak, D. K., Darıcı, H., & Karaö, E. (2020). *Stemcell Covid*. 11(5), 1174–1190.
- Kemendes RI. Situasi COVID-19. Kementerian Kesehatan RI. 2020. <https://infeksiemerging.kemkes.go.id>
- Kode, J. A., Mukherjee, S., Joglekar, M. V., & Hardikar, A. A. (2009). Mesenchymal stem cells: Immunobiology and role in immunomodulation and tissue regeneration. *Cytotherapy*, 11(4), 377–391.
- Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D., & Lessler, J. (2020). Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine*.
- Kusuma, G. D., Carthew, J., Lim, R., & Frith, J. E. (2017). Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. *Stem Cells and Development*, 26(9), 617–631.
- Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet (London, England)*, 363(9419), 1439–1441.
- Lippi, G., & Cervellin, G. (2018). Procalcitonin for diagnosing and monitoring bacterial infections: for or against? In *Clinical chemistry and laboratory medicine (Vol. 56, Issue 8, pp. 1193–1195)*.

- Ma, X., Ph, D., Wang, D., Ph, D., Xu, W., Wu, G., Gao, G. F., Phil, D., Tan, W., & Ph, D. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. 1–7.
- Martini, M., Testi, M. G., Pasetto, M., Picchio, M. C., Innamorati, G., Mazzocco, M., Ugel, S., Cingarlini, S., Bronte, V., Zanovello, P., Krampera, M., Mosna, F., Cestari, T., Riviera, A. P., Brutti, N., Barbieri, O., Matera, L., Tridente, G., Colombatti, M., & Sartoris, S. (2010). IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. *Vaccine*, 28(20), 3548–3557.
- Mattapally, S., Pawlik, K. M., Fast, V. G., Zumaquero, E., Lund, F. E., Randall, T. D., Townes, T. M., & Zhang, J. (2018). Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy. *Journal of the American Heart Association*, 7(23), e010239.
- McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020). The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmunity Reviews*, 19(6), 102537.
- Medzhitov, R. (2010). Inflammation 2010: New Adventures of an Old Flame. *Cell*, 140(6), 771–776.
- Merino-González, C., Zuñiga, F. A., Escudero, C., Ormazabal, V., Reyes, C., Nova-Lamperti, E., Salomón, C., & Aguayo, C. (2016). Mesenchymal stem cell-derived extracellular vesicles promote angiogenesis: Potencial clinical application. *Frontiers in Physiology*, 7(FEB), 1–9.
- Moll, G., Drzeniek, N., Kamhieh-Milz, J., Geissler, S., Volk, H.-D., & Reinke, P. (2020). MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy . In *Frontiers in Immunology* (Vol. 11, p. 1091).
- Moreau, P., Adrian-Cabestre, F., Menier, C., Guiard, V., Gourand, L., Dausset, J., Carosella, E. D., & Paul, P. (1999). IL-10 selectively induces HLA-G

- expression in human trophoblasts and monocytes. *International immunology*, 11(5), 803–811.
- Najar, M., Krayem, M., Meuleman, N., Bron, D., & Lagneaux, L. (2017). Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. *Immune Network*, 17(2), 89–102.
- Nasadyuk, C. (2016). Umbilical cord stem cells: biological characteristics, approaches to banking and clinical application. *Cell and Organ Transplantation*, 4(2), 230–235.
- Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*. 2020;323(18):1775–1776.
- Pillaiyar, T., Meenakshisundaram, S., & Manickam, M. (2020). Recent discovery and development of inhibitors targeting coronaviruses. *Drug Discovery Today*, 25(4), 668–688.
- Rawat, S., Gupta, S., & Mohanty, S. (2019). We are Intech Open , the world ' s leading publisher of Open Access books Built by scientists, for scientists. January.
- Robert, A., Weiss, R., Dahlke, M. H., Robert, A., & Weiss, R. (2019). Immunomodulation by Mesenchymal Stem Cells (MSCS): Mechanisms of Action of Living , Apoptotic , and Dead MSCS. 10(June), 1–10.
- Rodríguez, A., Reyes, L. F., Monclou, J., Suberviola, B., Bodí, M., Sirgo, G., Solé-Violán, J., Guardiola, J., Barahona, D., Díaz, E., Martín-Loeches, I., Restrepo, M. I., & on behalf GETGAG study group (2018). Relationship between acute kidney injury and serum procalcitonin (PCT) concentration in critically ill patients with influenza infection. *Medicina intensiva*, 42(7), 399–408.
- Sato, K., Yamawaki-Ogata, A., Kanemoto, I., Usui, A., & Narita, Y. (2016). Isolation and characterisation of peripheral blood-derived feline mesenchymal stem cells. *Veterinary Journal*, 216(September 2015), 183–188.
- Schett, G., Sticherling, M., & Neurath, M. F. (n.d.). COVID-19 : risk for cytokine targeting in chronic inflammatory diseases ? *Nature Reviews Immunology*, 3–4.

- Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*.
- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yuniastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, 7(1), 45
- Todeschi, M. R., El Backly, R., Capelli, C., Daga, A., Patrone, E., Introna, M., Cancedda, R., & Mastrogiacomo, M. (2015). Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration. *Stem cells and development*, 24(13), 1570–1581.
- Ullah, I., Subbarao, R. B., & Rho, G. J. (2015). Human mesenchymal stem cells - current trends and future prospective. *Bioscience Reports*, 35(2).
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*, 323(11), 1061–1069.
- Wang, Y., Huang, J., Gong, L., Yu, D., An, C., Bunpetch, V., Dai, J., Huang, H., Zou, X., Ouyang, H., & Liu, H. (2019). The Plasticity of Mesenchymal Stem Cells in Regulating Surface HLA-I. *IScience*, 15, 66–78.
- Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Müller, M. A., Niemeyer, D., Kelly, T. C. J., Vollmar, P., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Zwirgmaier, K., Drosten, C., Wendtner, C., Ph, D., Niemeyer, D., Ph, D., Kelly, T. C. J., ... Bleicker, T. (2020). Virological assessment of hospitalized cases of coronavirus disease 2019.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–1242.

- Yan, G., Lee, C. K., Lam, L. T. M., Yan, B., Chua, Y. X., Lim, A. Y. N., Phang, K. F., Kew, G. Sen, Teng, H., Ngai, C. H., Lin, L., Foo, R. M., Pada, S., Ng, L. C., & Tambyah, P. A. (2020). Covert COVID-19 and false-positive dengue serology in Singapore. *The Lancet Infectious Diseases*, 20(5), 536.
- Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Medicine*, 46(4), 586–590.
- Zheng, G., Huang, L., Tong, H., Shu, Q., Hu, Y., Ge, M., Deng, K., Zhang, L., Zou, B., Cheng, B., & Xu, J. (2014). Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respiratory Research*, 15(1), 39.
- Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). H13. Coronavirus Disease 2019 (COVID-19): A Perspective from China. *Radiology*, 200490.